

## **Supplementary Material**

An unsuccessful replication attempting to demarcate the boundary conditions of  
memory reconsolidation

Lotte E. Stemerding, Danielle Stibbe, Vanessa A. van Ast, Merel Kindt

## Supplementary Figures and Tables



**Supplementary Figure 1.** The order of stimulus presentation, which was fixed for all participants. Assignment of each colored fractal to the CS+ and CS- was counterbalanced, here only one version is shown where the CS+ is the blue fractal and the CS- is the yellow fractal.

	Current sample	Sevenster (2014)	BF <sub>10</sub>
N	91	52	-
Female/Male	62/29	41/11	0.48
Age (years)	20.6 (2.4)	21.1 (2.8)	0.38
STAI-T	38.5 (8.2)	36.7 (8.5)	0.38
ASI	11.5 (5.6)	9.9 (5.4)	0.64
US intensity	27.6 (20.7)	15.0 (8.4)	404.8

**Supplementary Table 1.** Sample characteristics of the current versus the original sample, and the BFs showing the evidence for a difference between the samples on each of the characteristics. All data are shown as mean (s.d.).

	Current sample				Sevenster (2014)			
	t = 0	t = 1	p	$\eta^2_p$	t = 0	t = 1	p	$\eta^2_p$
Systolic	115.2 (10.0)	103.9 (10.1)	< .001	.67	113.9 (13.1)	99.6 (12.2)	< .001	.61
Diastolic	71.8 (6.1)	66.6 (6.7)	< .001	.44	68.0 (8.3)	65.3 (8.7)	< .01	.13
Heart rate	82.0 (14.4)	57.4 (9.6)	< .001	.82	n/a	n/a	-	-
State anxiety	31.6 (8.6)	28.6 (6.6)	< .001	.21	33.8 (6.9)	32.6 (9.9)	< .001	.19

**Supplementary Table 2.** Differences in blood pressure, heart rate and state anxiety pre and post propranolol intake. To allow for a direct comparison of effect sizes, the analyses were performed using frequentist statistics. All data are shown as mean (s.d.).

## Supplementary Results

### *Main analyses repeated including gender as between-group factor*

To control for gender differences we added gender as between-group factor to our main analyses. To test for acquisition, we performed a Gender (male, female)  $\times$  Group (no PE, single PE, multiple PE)  $\times$  Stimulus (CS+, CS-)  $\times$  Trial (1-6) Bayesian repeated measures ANOVA. Similar to the main analysis, we found a main effect of Stimulus ( $BF_{\text{incl}} = 2.82e7$ ,  $F(85,1) = 23.02$ ,  $p < .001$ ,  $\eta^2_p = .21$ ) and Trial ( $BF_{\text{incl}} = 1.30e4$ ,  $F(425,5) = 4.73$ ,  $p < .001$ ,  $\eta^2_p = .05$ ), but evidence against a Stimulus  $\times$  Trial interaction ( $BF_{\text{incl}} = 0.12$ ,  $F(425,5) = 1.96$ ,  $p = .084$ ,  $\eta^2_p = .02$ ). We found no evidence for an effect of Gender (all  $BF_{\text{incl}} < 0.15$ ,  $p > .472$ ). To test for an effect of propranolol we performed a Stimulus (CS+, CS-)  $\times$  Gender  $\times$  Group Bayesian rm ANOVA on the first extinction trial. We found evidence against an effect of Stimulus ( $BF_{\text{incl}} = 0.37$ ,  $F(85,1) = 1.26$ ,  $p = .265$ ,  $\eta^2_p = .02$ ) or a Stimulus  $\times$  Group interaction ( $BF_{\text{incl}} = 0.11$ ,  $F(85,2) = 0.02$ ,  $p = .982$ ,  $\eta^2_p < .01$ ). We found no effects of or interactions with Gender (all  $BF_{\text{incl}} < 0.23$ ,  $p > .747$ ). On the first reinstatement test trial we found evidence for an effect of Stimulus ( $BF_{\text{incl}} = 36.05$ ,  $F(85,1) = 7.17$ ,  $p = .009$ ,  $\eta^2_p = .08$ ) but against a Stimulus  $\times$  Group interaction ( $BF_{\text{incl}} = 0.10$ ,  $F(85,2) = 0.27$ ,  $p = .767$ ,  $\eta^2_p < .01$ ). We found inconclusive or no effects of or interactions with Gender (all  $BF_{\text{incl}} < 0.78$ ,  $p > .153$ ). The results from these extra analyses are comparable to our main findings.

### *Main analyses repeated including US intensity as covariate*

To control for possible effects of US intensity on our results, we have added this variable as a covariate to our analyses. To test for acquisition, we performed a Group (no PE, single PE, multiple PE)  $\times$  Stimulus (CS+, CS-)  $\times$  Trial (1-6) Bayesian repeated measures ANOVA with US intensity as covariate. Similar to the main analysis, we found a main effect of Stimulus ( $BF_{\text{incl}} = 2.80e7$ ,  $F(87,1) = 12.71$ ,  $p < .001$ ,  $\eta^2_p = .13$ ) and Trial ( $BF_{\text{incl}} = 1.49e4$ ,  $F(435,5) = 4.32$ ,  $p < .001$ ,  $\eta^2_p = .05$ ), but evidence against a Stimulus  $\times$  Trial interaction ( $BF_{\text{incl}} = 0.12$ ,  $F(435,5) = 0.75$ ,  $p = .585$ ,  $\eta^2_p < .01$ ). We found no evidence for an effect of US intensity ( $BF_{\text{incl}} < 0.28$ ,  $p > .723$ ) or of any effects of Group (all  $BF_{\text{incl}} < 0.28$ ,  $p > .458$ ). To test for an effect of propranolol we performed a Stimulus (CS+, CS-)  $\times$  Group Bayesian rm ANOVA with US intensity as covariate on the first extinction trial. We found weak

evidence against an effect of Stimulus ( $BF_{\text{incl}} = 0.38$ ,  $F(87,1) = 0.07$ ,  $p = .788$ ,  $\eta^2_p < .01$ ) or a Stimulus  $\times$  Group interaction ( $BF_{\text{incl}} = 0.10$ ,  $F(87,2) = 0.15$ ,  $p = .864$ ,  $\eta^2_p < .01$ ), and weak evidence against an effect of US intensity ( $BF_{\text{incl}} = 0.67$ ,  $F(87,1) = 0.44$ ,  $p = .511$ ,  $\eta^2_p < .01$ ). On the first reinstatement test trial we found evidence for an effect of Stimulus ( $BF_{\text{incl}} = 36.03$ ,  $F(87,1) = 7.21$ ,  $p = .009$ ,  $\eta^2_p = .08$ ), but against a Stimulus  $\times$  Group interaction ( $BF_{\text{incl}} = 0.11$ ,  $F(87,2) = 0.14$ ,  $p = .872$ ,  $\eta^2_p < .01$ ). We also found no evidence of an effect of US intensity ( $BF_{\text{incl}} = 0.52$ ,  $F(87,1) = 0.59$ ,  $p = .445$ ,  $\eta^2_p < .01$ ). The results from these extra analyses are thus comparable to our main findings, and we find no effects of US intensity.

#### *Differential responding on all extinction trials*

To investigate differential responding on all extinction trials and to test for an extinction effect, we performed a Stimulus (CS+, CS-)  $\times$  Trial (1-12)  $\times$  Group Bayesian rm ANOVA. We found strong evidence for an effect of Stimulus ( $BF_{\text{incl}} = 5.49e18$ ,  $F(88,1) = 30.87$ ,  $p < .001$ ,  $\eta^2_p = .26$ ), showing that collapsed over all trials responding to the CS+ was larger than to the CS-. We further found evidence for an effect of Trial ( $BF_{\text{incl}} = 3.54e55$ ,  $F(968,11) = 29.45$ ,  $p < .001$ ,  $\eta^2_p = .25$ ), showing that for both the CS+ and the CS- FPS responding decreased. However, we found strong evidence against a Stimulus  $\times$  Trial interaction ( $BF_{\text{incl}} < 0.01$ ,  $F(968,11) = 0.72$ ,  $p = .722$ ,  $\eta^2_p < .01$ ) showing that differential responding did not decrease over the trials. Lastly, there was strong evidence against an interaction effect of Group (all  $BF_{\text{incl}} < 0.04$ ,  $p > .516$ ). These data show that while there was no difference between CS+ and CS- responding on the first extinction trial, fear retention appears to be quite strong across all extinction trials, with all groups showing poor extinction.

#### *Responding to the CS+ on the last acquisition versus the first extinction trial*

To test whether responding to the CS+ decreased on the first extinction trial compared to the last acquisition trial, we performed a Trial (last acquisition, first extinction)  $\times$  Group Bayesian rm ANOVA. We found evidence for a main effect of Trial ( $BF_{\text{incl}} = 1.27$ ,  $F(88,1) = 4.61$ ,  $p = .035$ ,  $\eta^2_p = .05$ ), but in absolute numbers responding on the first extinction trial was *larger* than on the last

acquisition trial (see main document Figure 2). We found inconclusive evidence for an effect of Group ( $BF_{\text{incl}} = 1.07$ ,  $F(88,2) = 2.76$ ,  $p = .069$ ,  $\eta^2_p = .06$ ).

*Results from the intermittent checks in the Bayesian sequential updating paradigm*

***Check 1, N = 60 (20 per group), 01/03/2021***

We found evidence for differential responding at the end of acquisition (last three CS+ trials versus last three CS- trials) in the no PE group ( $BF_{10} = 7.65$ ) and the multiple PE group ( $BF_{10} = 1463.48$ ), but not in the single PE group ( $BF_{10} = 1.15$ ). The Stimulus (CS+,CS-)  $\times$  Group rmANOVA showed support against an Stimulus  $\times$  Group interaction on the first extinction trial ( $BF_{\text{incl}} = 0.23$ ) and the first reinstatement trial ( $BF_{\text{incl}} = 0.26$ ). Data collection was continued because we did not reach the stopping criteria ( $BF_{10} > 10$ ) for acquisition in the no PE and single PE group.

***Check 2, N = 66 (22 per group), 18/03/2021***

We found evidence for differential responding at the end of acquisition (last three CS+ trials versus last three CS- trials) in the no PE group ( $BF_{10} = 6.20$ ) and the multiple PE group ( $BF_{10} = 2735.52$ ), but not in the single PE group ( $BF_{10} = 0.87$ ). The Stimulus (CS+,CS-)  $\times$  Group rmANOVA showed support against an Stimulus  $\times$  Group interaction on the first extinction trial ( $BF_{\text{incl}} = 0.21$ ) and the first reinstatement trial ( $BF_{\text{incl}} = 0.20$ ). Data collection was continued because we did not reach the stopping criteria ( $BF_{10} > 10$ ) for acquisition in the no PE and single PE group.

***Check 3, N = 72 (24 per group), 01/04/2021***


We found evidence for differential responding at the end of acquisition (last three CS+ trials versus last three CS- trials) in the no PE group ( $BF_{10} = 6.60$ ) and the multiple PE group ( $BF_{10} = 123.90$ ), but not in the single PE group ( $BF_{10} = 0.49$ ). The Stimulus (CS+,CS-)  $\times$  Group rmANOVA showed support against an Stimulus  $\times$  Group interaction on the first extinction trial ( $BF_{\text{incl}} = 0.26$ ) and the first reinstatement trial ( $BF_{\text{incl}} = 0.27$ ). Data collection was continued because we did not reach the stopping criteria ( $BF_{10} > 10$ ) for acquisition in the no PE and single PE group.

**Check 4, N = 78 (26 per group), 13/04/2021**


We found evidence for differential responding at the end of acquisition (last three CS+ trials versus last three CS- trials) in the no PE group ( $BF_{10} = 19.5$ ) and the multiple PE group ( $BF_{10} = 86.9$ ), but not in the single PE group ( $BF_{10} = 0.53$ ). The Stimulus (CS+,CS-)  $\times$  Group rmANOVA showed support against an Stimulus  $\times$  Group interaction on the first extinction trial ( $BF_{incl} = 0.17$ ) and the first reinstatement trial ( $BF_{incl} = 0.24$ ). Data collection was continued because we did not reach the stopping criteria ( $BF_{10} > 10$ ) for acquisition in the single PE group.

**Check 5, N = 84 (28 per group), 23/04/2021**

We found evidence for differential responding at the end of acquisition (last three CS+ trials versus last three CS- trials) in the no PE group ( $BF_{10} = 54.20$ ) and the multiple PE group ( $BF_{10} = 155.70$ ), but not in the single PE group ( $BF_{10} = 1.04$ ). The Stimulus (CS+,CS-)  $\times$  Group rmANOVA showed support against an Stimulus  $\times$  Group interaction on the first extinction trial ( $BF_{incl} = 0.16$ ) and the first reinstatement trial ( $BF_{incl} = 0.16$ ). Data collection was continued because we did not reach the stopping criteria ( $BF_{10} > 10$ ) for acquisition in the single PE group.



**Supplementary Figure 2.** Bayes factors of the acquisition test for each of the groups at every check. Green shaded area represents the stopping criterium for acquisition ( $BF > 10$ ). Scale on the y-axis is logarithmic for visualization purposes.



**Supplementary Figure 3.** Bayes factors of the extinction and reinstatement test (this test included a factor “Group”) at every check. Green shaded areas represent the stopping criteria in favor of the null ( $< 0.33$ ) and against the null ( $> 3.0$ ).